Search stocks

Find any stock by ticker or company name

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Watchlist
Markets
Calendar
Screener
News
About

GLUE - Monte Rosa Therapeutics, Inc.... | Finranks

Home

/

GLUE

M

Monte Rosa Therapeutics, Inc. (GLUE)

NMS – Real Time Price. Currency in USD

16.14

+0.38 (2.38%)

Market open: Aug 12, 2026, 10:12 AM EDT

15.76

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Total Assets

Total Liabilities

Stockholders Equity

Total Debt

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

124M

76M

0

0

Cost of goods sold

-8M

-8M

-6M

-9M

Gross Profit

115M

68M

-6M

-9M

Operating expenses (excl. COGS)

-170M

-149M

-137M

-104M

Operating Income

-54M

-81M

-143M

-112M

Non-operating income, total

14M

11M

8M

4M

Pretax income

-40M

-70M

-135M

-109M

Equity in earnings

0

0

0

0

Taxes

1M

-3M

-338K

0

Non-controlling/minority interest

0

0

0

0

After tax other income/expense

0

0

0

0

Net income before discontinued operations

-39M

-73M

-135M

-109M

Discontinued operations

0

0

0

0

Net income

-39M

-73M

-135M

-109M

Dilution adjustment

0

0

0

0

Preferred dividends

0

0

0

0

Name

2025

2024

2023

2022

Total assets

449M+2.3%

439M+44.4%

304M-11.3%

342M

Total current assets

393M

377M

236M

276M

Total non-current assets

55M

61M

68M

67M

Total liabilities

216M-0.1%

216M+73.3%

125M+75.4%

71M

Total current liabilities

64M

157M

47M

26M

Total non-current liabilities

151M

59M

78M

45M

Total equity

233M

223M

179M

271M

Total liabilities & shareholders' equities

449M

439M

304M

342M

Total debt

39M-8.3%

43M-7.2%

46M-2.0%

47M

Name

2025

2024

2023

2022

Cash from operating activities

-23M

42M

-44M

-92M

Cash from investing activities

-102M

-44M

89M

-219M

Cash from financing activities

30M

99M

27M

20M

Free cash flow

-27M-172.3%

38M+160.5%

-63M+40.4%

-105M